

09/578,693

JB 05/20/2009

[Appl. No. 09/578,693
Response filed on September 10, 2001]

the BamHI recognition site after the termination codon, and
encodes the desired full-length human L-FABP.--

JB Please replace the paragraph beginning at page 26, line 20
and ending at page 27, lines 1-16 with the following replacement
paragraph:

A7 --The obtained cells were broken by ultrasonic, and the
cell extract was dialyzed against 5 mM Tris-HCl buffer (pH 8.5).
The resultant was separated by anion exchange column (RESOURCE Q
6 ml, manufactured by Pharmacia, Inc.), eluted with a solvent of
linear gradient to 300 mM NaCl, and the fraction showing ANS-
binding activity was collected. The fraction was concentrated by
ultra filtration with Centriprep (manufactured by AMICON LTD.),
and separated by gel filtration column (SUPERDEX™ 75pg,
manufactured by Pharmacia Inc.), and the fraction showing ANS-
binding activity was collected to give a human L-FABP fusion
protein. To the human L-FABP fusion protein thus obtained was
added Factor Xa (manufactured by New England Biolabs Inc.) in
1/100 weight, and the mixture was reacted at room temperature
overnight for restriction degradation. The reaction solution
after the enzyme treatment was separated again by gel
filtration, and the fraction of about 14 kilodalton showing